Who are Sr-89's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): [Ga-68]PSMA, 18F-rhPSMA-7.3, Rubidium-82, Copper Cu 64 Dotatate, Dexamethasone plus Radium-223, PET Scan with [18F] VAT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sr-89.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Sr-89 — Competitive Intelligence Brief

Sr-89 (Sr-89) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical; beta-emitting radioisotope. Area: Oncology.

marketed Radiopharmaceutical; beta-emitting radioisotope Bone hydroxyapatite (calcium analog); osteoblasts in areas of increased bone metabolism Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Sr-89 (Sr-89) — Peking Union Medical College Hospital. Strontium-89 is a beta-emitting radioisotope that localizes to areas of increased bone metabolism and delivers targeted radiation to relieve bone pain in patients with skeletal metastases.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sr-89 TARGET	Sr-89	Peking Union Medical College Hospital	marketed	Radiopharmaceutical; beta-emitting radioisotope	Bone hydroxyapatite (calcium analog); osteoblasts in areas of increased bone metabolism
[Ga-68]PSMA	[Ga-68]PSMA	Norbert Avril, M.D.	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
18F-rhPSMA-7.3	18F-rhPSMA-7.3	Hackensack Meridian Health	marketed	PET imaging agent / radiopharmaceutical	PSMA (prostate-specific membrane antigen)
Rubidium-82	Rubidium-82	Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	marketed	PET radiopharmaceutical	Na+/K+-ATPase pump (myocardial uptake mechanism)
Copper Cu 64 Dotatate	Copper Cu 64 Dotatate	Vanderbilt-Ingram Cancer Center	marketed	Radiopharmaceutical; somatostatin receptor agonist imaging agent	Somatostatin receptor 2 (SSTR2)
Dexamethasone plus Radium-223	Dexamethasone plus Radium-223	University Health Network, Toronto	marketed	Combination therapy: corticosteroid plus alpha-emitting radiopharmaceutical	Radium-223 targets calcium-mimetic bone uptake; dexamethasone targets glucocorticoid receptor
PET Scan with [18F] VAT	PET Scan with [18F] VAT	Stony Brook University	marketed	PET imaging agent / Radiopharmaceutical	Vascular adhesion molecules (VAM)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical; beta-emitting radioisotope class)

Peking Union Medical College Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sr-89 — Competitive Intelligence Brief. https://druglandscape.com/ci/sr-89. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab